Shanghai S.E.
06:00:00 2024-05-09 pm EDT
5-day change
1st Jan Change
9.71
CNY
-2.22%
+3.41%
-11.73%
Getein Biotech, Inc authorizes a Buyback Plan.
The Board of Directors of Getein Biotech, Inc has authorized a buyback plan on December 30, 2020.
Getein Biotech, Inc Reports Earnings Results for the First Quarter Ended March 31, 2024
Apr. 29
CI
Getein Biotech, Inc Reports Earnings Results for the Full Year Ended December 31, 2023
Apr. 29
CI
Getein Biotech, Inc Reports Earnings Results for the Nine Months Ended September 30, 2023
23-10-27
CI
Getein Biotech, Inc Reports Earnings Results for the Half Year Ended June 30, 2023
23-08-28
CI
Getein Biotech, Inc Reports Earnings Results for the First Quarter Ended March 31, 2023
23-04-26
CI
Getein Biotech, Inc Reports Earnings Results for the Full Year Ended December 31, 2022
23-03-30
CI
Meihua International Unit, Getein Biotech to Develop COVID-19 Antigen Test Kits, Other In Vitro Diagnostic Products
23-01-11
MT
Meihua International Medical Technologies Co., Ltd. Enters into Strategic Partnership with Getein Biotech Inc. to Jointly Produce and Sell Covid-19 Antigen Test Kits and IVDs
23-01-11
CI
Getein Biotech Gets Regulatory Approval for COVID-19 Kit; Shares Up 9%
22-12-12
MT
Getein Biotech, Inc Reports Earnings Results for the Nine Months Ended September 30, 2022
22-10-26
CI
Yestar Healthcare, Getein Biotech End Investment Talks
22-08-24
MT
Getein Biotech, Inc Reports Earnings Results for the Half Year Ended June 30, 2022
22-08-23
CI
Yestar Healthcare Holdings Company Limited cancelled the transaction announced on April 8, 2022
22-08-22
CI
Getein Biotech, Inc Reports Earnings Results for the First Quarter Ended March 31, 2022
22-04-27
CI
Yestar Healthcare Holdings Company Limited announced that it expects to receive funding from Getein Biotech, Inc
22-04-07
CI
Getein Biotech, Inc Reports Earnings Results for the Full Year Ended December 31, 2021
22-03-11
CI
Sichuan Getein Biotechnology Co., Ltd. announced that it expects to receive CNY 30 million in funding from Getein Biotech, Inc
22-02-23
CI
Getein Biotech, Inc Reports Earnings Results for the Nine Months Ended September 30, 2021
21-10-27
CI
Getein Biotech, Inc Reports Earnings Results for the Half Year Ended June 30, 2021
21-08-17
CI
Tranche Update on Getein Biotech, Inc's Equity Buyback Plan announced on December 31, 2020.
21-06-29
CI
Getein Biotech, Inc's Equity Buyback announced on December 30, 2020, has expired with 1,560,790 shares, representing 0.43% for CNY 50 million.
21-06-28
CI
KK Culture : Unit Seals COVID-19 Kits Distribution Deal with Getein Biotech; Shares Slump 11%
21-05-26
MT
Getein Biotech, Inc Reports Earnings Results for the First Quarter Ended March 31, 2021
21-04-27
CI
Tranche Update on Getein Biotech, Inc's Equity Buyback Plan announced on December 31, 2020.
21-04-01
CI
Akang Health announced that it has received CNY 200 million in funding from China Science & Merchants Investment Management Group Co., Ltd., CICC Investment Group Company Limited, Getein Biotech, Inc, China Science and Tech Innovation Venture Capital Management, Nanjing Jidan Equity Investment Management Co., Ltd. and other investors
21-03-15
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Getein Biotech Inc is a China-based company mainly engaged in the research and development, production and sales of in vitro diagnostic reagents and instruments. Its in vitro diagnostic reagents include Point-of-care Testing (POCT) reagents, chemiluminescence reagents, biochemical reagents, blood cell reagents, hemagglutination reagents and others. Its diagnostic instruments include immunoquantitative analyzer FIA 8000, immunoquantitative analyzer FIA 8600, fluorescence immunoquantitative analyzer Getein 1100, fluorescence immunoquantitative analyzer Getein 1180, automatic biochemical analyzer CM 400, automatic chemiluminescence analyzer MAGICL 6000 and five classification blood cell analyzer BHA-5000, among others. The Company also provides testing and agency services. The Company distributes its products within domestic market and to overseas markets.
More about the company
1st Jan change
Capi.
-11.73% 697M -1.29% 12.64B -0.47% 8.37B +5.68% 5.37B +22.23% 5.26B -2.03% 4.58B -52.89% 3.16B +19.30% 2.89B -8.42% 2.22B -3.55% 1.91B
Diagnostic & Testing Substances
+951% of historical
More than 20 years
Our Experts
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
GETEIN BIOTECH, INC 